ArticleBiomaterials2011
The effect of biophysical attributes of the ocular trabecular meshwork associated with glaucoma on the cell response to therapeutic agents.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 83 citations in OpenAlex.
- Segmental Mechanobiology of Normal and Glaucomatous Human Trabecular Meshwork Cells.ACS measurement science au · 2026Article
- Bioengineered 3D Human Trabecular Meshwork Models for Outflow Physiology and Glaucoma Research.Bioengineering (Basel, Switzerland) · 2026Review
- Possible Effects of Topical Rho-Kinase Inhibitor on Schlemm's Canal Morphology Parameters.Biomedicines · 2026Article
- 3D traction force microscopy in human trabecular meshwork tissues: Effects of ROCK and YAP/TAZ inhibition in normal and glaucomatous tissues.Tissue & cell · 2025Article
- Article
- Extracellular vesicles as emerging players in glaucoma: Mechanisms, biomarkers, and therapeutic targets.Vision research · 2025Review
- Comparative analysis of traction forces in normal and glaucomatous trabecular meshwork cells within a 3D, active fluid-structure interaction culture environment.Acta biomaterialia · 2024Article
- Dynamic traction force in trabecular meshwork cells: A 2D culture model for normal and glaucomatous states.Acta biomaterialia · 2024Article
- Non-Viral Gene Therapy in Trabecular Meshwork Cells to Prevent Fibrosis in Minimally Invasive Glaucoma Surgery.Pharmaceutics · 2022Article
- YAP/TAZ Mediate TGFβ2-Induced Schlemm's Canal Cell Dysfunction.Investigative ophthalmology & visual science · 2022Article
- Extracellular Matrix Stiffness and TGFβ2 Regulate YAP/TAZ Activity in Human Trabecular Meshwork Cells.Frontiers in cell and developmental biology · 2022Article
- Photoinduced Gelatin-Methacrylate Scaffolds to Examine the Impact of Extracellular Environment on Trabecular Meshwork Cells.Industrial & engineering chemistry research · 2021Article
- The Application of Nitric Oxide for Ocular Hypertension Treatment.Molecules (Basel, Switzerland) · 2021Review
- Normal and glaucomatous outflow regulation.Progress in retinal and eye research · 2021Review
- TET-dependent GDF7 hypomethylation impairs aqueous humor outflow and serves as a potential therapeutic target in glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Human trabecular meshwork cell behavior is influenced by collagen scaffold pore architecture and glycosaminoglycan composition.Biotechnology and bioengineering · 2020Article
- Tissue-Engineered Models for Glaucoma Research.Micromachines · 2020Review
- Fast automated processing of AFM PeakForce curves to evaluate spatially resolved Young modulus and stiffness of turgescent cells.RSC advances · 2020Article
- Endogenous ocular lipids as potential modulators of intraocular pressure.Journal of cellular and molecular medicine · 2020Article
- Modulation of human corneal stromal cell differentiation by hepatocyte growth factor and substratum compliance.Experimental eye research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Glaucoma is a devastating neurodegenerative disease, which can lead to vision loss and is associated with irreversible damage to retinal ganglion cells. Although the mechanism of disease onset remains unknown, we have recently demonstrated that the stiffness of the ocular trabecular meshwork (HTM) increases dramatically in human donor eyes with a history of glaucoma. Here we report that polyacrylamide hydrogels, which mimic the compliant conditions of normal and glaucomatous HTM, profoundly modulate cytoskeletal dynamics and the elastic modulus of the overlying HTM cells. Substratum compliance also modulates HTM cell response to Latrunculin-B, a cytoskeletal disrupting agent currently in human clinical trials for the treatment of glaucoma. Additionally, we observed a compliance-dependent rebound effect of Latrunculin-B with an unexpected increase in HTM cell elastic modulus being observed upon withdrawal of the drug. The results predict that cytoskeletal disrupting drugs may be more potent in advanced stages of glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.